Tripoint Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TRIPOINT
TRIPOINT has one approved drug.
There are five US patents protecting TRIPOINT drugs.
There are twenty-three patent family members on TRIPOINT drugs in eighteen countries and two supplementary protection certificates in two countries.
Summary for Tripoint
| International Patents: | 23 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Tripoint
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-002 | Dec 20, 2018 | DISCN | Yes | No | 8,425,938 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-002 | Dec 20, 2018 | DISCN | Yes | No | 8,163,306 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | DISCN | Yes | No | 8,535,717 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | DISCN | Yes | No | 8,431,156 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Tripoint
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-002 | Dec 20, 2018 | 8,535,717 | ⤷ Start Trial |
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | 8,425,938 | ⤷ Start Trial |
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-002 | Dec 20, 2018 | 8,425,938 | ⤷ Start Trial |
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | 8,535,717 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Tripoint Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 1663175 | ⤷ Start Trial |
| China | 1856299 | ⤷ Start Trial |
| Australia | 2011200881 | ⤷ Start Trial |
| African Regional IP Organization (ARIPO) | 200603602 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tripoint Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0162036 | 2000C/032 | Belgium | ⤷ Start Trial | PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329 |
| 0162036 | C300028 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
